Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients.

For the most interesting combinations indicated from our study, that is, simvastatin combined with protein kinase inhibitors, a small randomized trial showed a trend towards superiority for simvastatin combined with gefitinib but no effect when combined with afatinib in nonsmall cell lung cancer, in both cases without obvious signs of more toxicity [ 37 , 38 ].

also in 53,322 other papers